therapeutic substances of human origin" means human blood and its derivatives (whole human blood, dried human plasma, human albumin and fixed solutions of human plasma protein, human immunoglobulin and human fibrinogen),

therapeutic substances of human origin" means human blood and its derivatives (whole human blood, dried human plasma, human albumin and fixed solutions of human plasma protein, human immunoglobulin and human fibrinogen),

In a most preferred embodiment of the present invention, the third segment comprises amino acid residues (414-427) of the native human fibrinogen η' sequence.

therapeutic substances of human origin’ means human blood and its derivatives (whole human blood, dried human plasma, human albumin and fixed solutions of human plasma protein, human immunoglobulin and human fibrinogen);

therapeutic substances of human origin" means human blood and its derivatives (whole human blood, dried human plasma, human albumin and fixed solutions of human plasma protein, human immunoglobulin and human fibrinogen),

A digestion product of human fibronopeptide A or a digestion product of human fibrinogen α-E chain is used as a marker peptide.

Methods are provided for the stable storage of ready-to-use, biocompatible human fibrinogen, which despite its concentration, remains available in fluid form, and which will permit long-term rapid and easy processing into a tissue adhesive preparation.

Patients given human fibrinogen should be observed closely for signs or symptoms of thrombosis.

Patients given human fibrinogen should be observed closely for signs or symptoms of thrombosis.

The enzyme of present invention is a serine proteinase capable of hydrolyzing alpha chain of human fibrinogen, and has a molecular weight of 29.3~29.5kD and an isoelectric point of 5.5.

Patients given human fibrinogen should be observed closely for signs or symptoms of thrombosis.

A monoclonal antibody that reacts with a human soluble fibrin but not with a human fibrinogen; a hybridoma that secretes the above antibody; and a method of assaying a human soluble fibrin with the above antibody.

There is a risk of thrombosis when patients are treated with human fibrinogen particularly with high dose or repeated dosing.

Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (FXIIIa) and calcium ions, is converted into a stable and elastic three-dimensional fibrin haemostatic clot.

LFB SA announces it has obtained the first three European marketing authorisations for its human fibrinogen, in Germany, Denmark and Hungary, via a decentralised licensing procedure.

Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (FXIIIa) and calcium ions, is converted into a stable and elastic three-dimensional fibrin haemostatic clot.